Males. You must agree to the following during the study and for at least 90 days after the last dose of study drug: • Refrain from donating sperm PLUS either • Be abstinent from heterosexual intercourse as your preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use birth control/barrier as detailed below: • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of birth control as a condom may break or leak when having sexual intercourse with a female able to have children who is not currently pregnant • In addition to male condom use, a highly effective method of birth control may be considered in female partners able to have children of male participants Highly effective methods of birth control include: • Implantable progestogen-only hormone birth control • Intrauterine device (IUD) • Intrauterine hormone-releasing system (IUS) • Bilateral tubal occlusion (both tubes blocked) which includes bilateral tubal ligation (both tubes tied) • Partner has a vasectomy (absence of sperm confirmed) • Hormonal birth control*(See Note Below) • Sexual abstinence – defined as refraining from heterosexual intercourse and is the preferred and usual lifestyle of the participant PLUS *Note: One of the following barrier methods must be used in addition to the hormonal birth control methods: • Male or female condom with or without spermicide • Cervical cap, diaphragm, or sponge with spermicide • A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods) Pregnancy-Related Risks The effects of the study drug on the following are not known and may involve unforeseeable risks: • Fertility • Sperm • Pregnancy • Unborn child • Breastfeeding child Even if you use birth control during the study, there is a chance your partner could become pregnant. If your partner is pregnant or becomes pregnant during the study, the study drug or procedure may involve unforeseeable risks to the unborn child. A pregnancy test is not always right, especially in the early stages of pregnancy. You cannot participate in this study if: • You are a man whose female partner is currently pregnant or planning to become pregnant If you want to stop your required birth control during the study, you should tell the study investigator immediately. You will be taken out of the study if you stop using birth control.
Males a) Hair, when combed, brushed, picked, blown, teased, or otherwise worn, will not exceed two inches (2") in height.
Males. 1 Shirt and 1 pair Pants or 1 pair Shorts and 1 Shirt; OR
Males. You must agree to the following during the study and for at least 90 days after the last dose of study drug: • Refrain from donating sperm PLUS either • Be abstinent from heterosexual or homosexual intercourse as your preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use birth control/barrier as detailed below: • Agree to use a male condom when engaging in any activity that allows for the passage of ejaculate to another person • Male participants should be advised of the benefit for a female partner to use a highly effective method of birth control as a condom may break or leak when having sexual intercourse with a female able to have children who is not currently pregnant. They must inform their female partner(s) of the risk and strongly recommend she uses a highly effective method of birth control Highly effective methods of birth control include: Low user dependency methods (methods that do not rely on you to remember to use them) • Implantable hormone birth control • Intrauterine device (IUD) • Intrauterine hormone-releasing system (IUS) • Bilateral tubal occlusion (both tubes blocked) which includes bilateral tubal ligation (both tubes tied) • Vasectomy (absence of sperm confirmed) User dependent methods (methods that rely on you to remember to use them) • Hormonal birth control • Sexual abstinence – defined as refraining from heterosexual intercourse and is the preferred and usual lifestyle of the participant The study doctor or study staff will discuss these contraceptive methods with you.
Males. You must agree to the following during the study and for at least 28 days after the last dose of study drug. Refrain from donating sperm PLUS either Be abstinent from heterosexual intercourse with a female able to have children as your preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use birth control as detailed below: Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. In addition to male condom use, female partners able to have children may consider an additional highly effective birth control method such as the methods detailed earlier in this document and the following: U ser dependent methods (methods that rely on you to remember to use them) Combined (estrogen and progestogen containing) hormonal birth control o Oral o Intravaginal o Transdermal Progestogen containing hormonal birth control o Oral o Injectable Be abstinent from heterosexual intercourse as your preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent during the entire risk period N ote: For female partners able to have children, one of the following barrier methods must be used in a ddition to the user dependent birth control methods detailed above: Male or female condom with or without spermicide Cervical cap, diaphragm, or sponge with spermicide A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods) Pregnancy-Related Risks The effects of the study drug on the following are not known and may involve unforeseeable risks: Sperm Pregnancy Unborn child Breastfeeding child The effects of the study drug on reproduction are unknown. At this time, it is not known whether the study drug can cause harm to the fetus or whether it is secreted in human milk. Therefore, the study drug should not be administered to pregnant women or women who are breastfeeding. An appropriate method of contraception is required. Even if you use birth control during the study, there is a chance you or your partner, could become pregnant. If you or your partner are pregnant or become pregnant, during the study, the study drug or procedure may involve unforeseeable risks to the unborn child. A pregnancy test is not always right, especially in the early stages of pregnancy. If you are currently pregnant, plan to become pregnant, or are breastfeedi...
Males. A 1:1 mating scheme is employed. Males may be live-spawned on the first spawning day as necessary to make up for a low naturally-occurring male to female ratio. However, inclusion of xxxx xxxxxxx in the run-at-large broodstock collections helps to alleviate occasional low adult male occurrence.
Males. The effects of rezafungin on reproduction (i.e. abnormalities in offspring or a decrease in the ability to get a partner pregnant) have shown potential risks in men (sperm abnormalities). Even if you use birth control during the study, there is a chance your partner could become pregnant. If your partner becomes pregnant during the study, the study drug may involve unforeseeable risks to the unborn baby. Therefore, if you have not had a vasectomy, you must agree to use condoms with spermicide for birth control from the first day of the study until at least 18 weeks (126 days) after your last dose of rezafungin. You must also not donate sperm from the first day of the study until at least 18 weeks (126 days) after the last dose of rezafungin. If at any time during the study, your female partner becomes pregnant, you must immediately contact the study doctor.
Males. We do not insist on neutering. If you don't believe the findings of the new studies then we recommend a vasectomy vice castration. If you insist on neutering wait until the dog is 18 months old.
Males. The males showed an increase in time spent on the open arm from a single (M = 13.33, SEM = 1.83) to a repeated dose of ethanol (M = 26.42, SEM = 3.31; Fig. 2b; t26=3.59, p=0.001) An increase in time spent on the open with increased exposure to ethanol indicates rapid sensitization to the anxiolytic effects of ethanol. A XXXXX print-out, representative image, displays the time spent in each region of interest in a visual format (Fig 2c). This is labeled as an ethogram, although location of the animal is shown, rather than specific behavior. Machine scored data (DeepLabCut) Females However, when the data was processed using DeepLabCut, there was much wide variability, which most likely impacted the reliability of the results. Females showed no significant interaction between the estrous status of the animal and ethanol exposure (F1,26=0.5, p=0.48). Another measure of anxiolytic behavior is to look at the nose dips, or when a mouse extends its nose past the edge of the EPM, so they can see the height off of the EPM. In the females, we saw no significant interaction between estrous status and exposure to ethanol (F1,20=0.00, p=0.857) in nose dips. Diestrus females that received a single exposure to ethanol had a mean of 3.75 with an SEM of 1.181, while the repeated exposure group had a mean of 4.00 and an SEM of 1.183. Similarly estrus females that received a single exposure to ethanol had a mean of 4.5 with an SEM of 1.041, while the repeated exposure group had a mean of 5.250 and an SEM of 1.109.
Males. The results were similar to the results using XXXXX, with a significant impact of a ethanol exposure on the percent time the animal spent in the open arm (t16.04=2.179, p=0.045). The single exposure group (M = 13.33, SEM = 1.829) was significantly less than the repeated exposure group (M = 26.42, SEM = 3.31), showing an increase in anxiolytic behavior with increased alcohol exposure. The males are showing rapid sensitization to the anxiolytic effects of alcohol. Males showed no significant difference in nose dips between the group that received a single dose and the group that had repeated doses, although it was a marginal effect (Fig. 3d; t24=1.478, p=0.152). The single exposure group (M = 3.769, SEM = 0.856) was significantly less than the repeated exposure group (M = 5.615, SEM = 0.910), showing an increase in anxiolytic behavior with increased alcohol exposure. The males are showing a trend towards rapid sensitization to the anxiolytic effects of alcohol.
